Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need.
Yasinskaya Y, Bala S, Waack U, Dixon C, Higgins K, Moore JN, Jjingo CJ, O'Shaughnessy E, Colangelo P, Botgros R, Nambiar S, Angulo D, Dane A, Chiller T, Hodges MR, Sandison T, Hope W, Walsh TJ, Pappas P, Katragkou A, Kovanda L, Rex JH, Marr KA, Ostrosky-Zeichner L, Sekine S, Deshpande M, Shukla SJ, Farley J. Yasinskaya Y, et al. Among authors: moore jn. Clin Infect Dis. 2023 Aug 14;77(3):380-387. doi: 10.1093/cid/ciad195. Clin Infect Dis. 2023. PMID: 37021650
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs.
O'Shaughnessy E, Yasinskaya Y, Dixon C, Higgins K, Moore J, Reynolds K, Ampel NM, Angulo D, Blair JE, Catanzaro A, Galgiani JN, Garvey E, Johnson R, Larwood DJ, Lewis G, Purdie R, Rex JH, Shubitz LF, Stevens DA, Page SJ, Shukla SJ, Farley JJ, Nambiar S. O'Shaughnessy E, et al. Among authors: moore j. Clin Infect Dis. 2022 Jun 10;74(11):2061-2066. doi: 10.1093/cid/ciab904. Clin Infect Dis. 2022. PMID: 34651656
FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type Colorectal Cancer.
Casak SJ, Horiba MN, Yuan M, Cheng J, Lemery SJ, Shen YL, Fu W, Moore JN, Li Y, Bi Y, Auth D, Fesenko N, Kluetz PG, Pazdur R, Fashoyin-Aje LA. Casak SJ, et al. Among authors: moore jn. Clin Cancer Res. 2023 Nov 1;29(21):4326-4330. doi: 10.1158/1078-0432.CCR-23-1041. Clin Cancer Res. 2023. PMID: 37318379 Free PMC article.
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer.
Fusco MJ, Casak SJ, Mushti SL, Cheng J, Christmas BJ, Thompson MD, Fu W, Wang H, Yoon M, Yang Y, Moore JN, Bi Y, Nan Y, Long CE, Auth D, Rahman NA, Tang S, Pazdur R, Fashoyin-Aje LA, Kluetz PG, Lemery SJ. Fusco MJ, et al. Among authors: moore jn. Clin Cancer Res. 2024 Aug 1;30(15):3100-3104. doi: 10.1158/1078-0432.CCR-24-0281. Clin Cancer Res. 2024. PMID: 38809262 Clinical Trial.
The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model.
Inselman AL, Masters EA, Moore JN, Agarwal R, Gassman A, Kuijpers G, Beger RD, Delclos KB, Swift S, Camacho L, Vanlandingham MM, Sloper D, Nakamura N, Gamboa da Costa G, Woodling K, Bryant M, Trbojevich R, Wu Q, McLellen F, Christner D. Inselman AL, et al. Among authors: moore jn. Front Pharmacol. 2024 Apr 16;15:1365151. doi: 10.3389/fphar.2024.1365151. eCollection 2024. Front Pharmacol. 2024. PMID: 38689663 Free PMC article.
282 results